Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer.
Saeedeh RastakhizMona YazdaniSheida ShariatAtefeh ArabAmir Abbas Momtazi-BorojeniNastaran BaratiMercedeh MansourianMohamdreza AminAzam AbbasiZahra SaberiSeyed Amir JalaliAli BadieeMahmoud Reza JaafariPublished in: Journal of cellular biochemistry (2018)
The study was aimed at evaluating antitumor and immunomodulatory effects of liposomal vaccine composed of P5 human epidermal growth factor receptor 2 (HER2)/neu-derived peptide coupled to the surface of high-temperature nanoliposomes containing distearoylphosphocholine:distearoylphosphoglycerol:Chol:dioleoylphosphatidylethanolamine (DOPE) comprising monophosphoryl lipid A (MPL) adjuvant in HER2/neu overexpressing the breast cancer model. BALB/c mice bearing TUBO carcinoma were subcutaneously immunized with formulations containing 10 µg P5 peptide and 25 µg MPL three times with 2-week intervals. To determine immuno responses in immunized mice, the amount of released interferon-γ and IL-4 were measured by the enzyme-linked immunospot method and the flow cytometric analysis on the isolated splenocytes. The results demonstrated that tumor-bearing mice immunized with Lip/DOPE/MPL/P5 formulation had the most released interferon-γ and the highest cytotoxic T lymphocyte responses that led to the lowest tumor size and the longest survival time than those of other formulations. The results achieved by Lip/DOPE/MPL/P5 formulation could make it a suitable candidate to induce effective antigen-specific tumor immunity against breast cancer.
Keyphrases
- epidermal growth factor receptor
- high fat diet induced
- early stage
- drug delivery
- endothelial cells
- dendritic cells
- tyrosine kinase
- advanced non small cell lung cancer
- randomized controlled trial
- type diabetes
- immune response
- metabolic syndrome
- wild type
- insulin resistance
- high resolution
- fatty acid
- skeletal muscle
- breast cancer risk
- study protocol
- childhood cancer